On August 28, 2019, the first implantation of the self-developed VitaFlow® Aortic Valve System of MicroPort CardioFlow was performed at Zhongshan Hospital affiliated to Fudan University. Prof. Ge Junbo, Academician of Chinese Academy of Sciences, Director of the Cardiology Department of Zhongshan Hospital, performed the surgery and successfully implanted the VitaFlow® aortic valve into a 70-year-old male patient.
Since the launch of VitaFlow® series of TAVI products, MicroPort CardioFlow has entered into over 300 heart centers across China, becoming a major player in the Chinese heart valve market.
Shanghai, China, 29 March 2022 - MicroPort CardioFlow today announced the annual results of the Company and its subsidiaries for the 12 months ended December 31, 2021. In the Reporting Period, MicroPort CardioFlow recorded revenue of RMB200.8 million, representing a year-on-year growth of 93.2%. In addition to the significant growth in revenue, the gross profit margin also improved drastically by 15.4 percentage points to 59.1%.
MicroPort CardioFlow recently announced that its transcatheter aortic valve implantation (TAVI) solution, the new-generation VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™) has received marketing approval by the Argentine National Administration of Drugs, Foods, and Medical Devices (ANMAT).
On 30th August 2021, MicroPort CardioFlow, announced that its transcatheter aortic valve system – VitaFlow Liberty™ has received approval for marketing by China’s National Medical Products Administration. As the first motorized retrievable transcatheter aortic valve system approved for marketing, VitaFlow Liberty™ leads as the first motorized retrievable system in the TAVI market.
